Ownership and insider activity for Novavax, Inc. (NVAX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials.
Price
| Price | $9.35 |
| Market Cap | $1.5B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-20 | Rodgers Richard J | M-Exempt | 18,880 | |
| 2026-06-18 | Rodgers Richard J | A-Award | 21,270 | $194K |
| 2026-06-18 | Rodgers Richard J | A-Award | 14,180 | |
| 2026-06-20 | Rodgers Richard J | M-Exempt | 18,880 | |
| 2026-06-20 | King Rachel K. | M-Exempt | 18,880 | |
| 2026-06-18 | King Rachel K. | A-Award | 21,270 | $194K |
| 2026-06-18 | King Rachel K. | A-Award | 14,180 | |
| 2026-06-20 | King Rachel K. | M-Exempt | 18,880 | |
| 2026-06-20 | DOUGLAS RICHARD | M-Exempt | 18,880 | |
| 2026-06-18 | DOUGLAS RICHARD | A-Award | 21,270 | $194K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $144.4M | $106.3M | $70.2M | $78.8M | $553.4M | $1.52B | $1.34B | $568.5M | $530.2M | $240.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | $157.6M | 0 | 0 | 0 | $392.9M | $494.4M |
| Receivables | $233000 | 0 | 0 | $7.5M | $262.0M | $455.0M | $82.4M | $297.2M | $108.3M | $106.4M |
| Inventory | $15.7M | $13.1M | $12.0M | 0 | 0 | $8.9M | $36.7M | $41.7M | $8.7M | $11.5M |
| Total Current Assets | $287.8M | $203.3M | $119.3M | $97.2M | $1.25B | $2.16B | $1.70B | $1.14B | $1.13B | $978.3M |
| Property, Plant & Equipment | $40.2M | $36.0M | $28.4M | $11.4M | $180.0M | $228.7M | $400.5M | $491.0M | $300.0M | $67.7M |
| Goodwill | $51.7M | $53.6M | $52.0M | $51.2M | $135.4M | $131.5M | $126.3M | $127.5M | $107.5M | $113.5M |
| Intangible Assets | $9.2M | $7.9M | $6.5M | $5.6M | $5.7M | $4.8M | 0 | 0 | 0 | 0 |
| Total Assets | $394.3M | $302.5M | $208.0M | $173.0M | $1.58B | $2.58B | $2.26B | $1.80B | $1.56B | $1.18B |
| Accounts Payable | $5.7M | $5.6M | $9.3M | $2.9M | $54.3M | $127.0M | $216.5M | $132.6M | $41.6M | $24.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $324.9M | 0 | 0 | 0 |
| Total Current Liabilities | $66.4M | $73.7M | $45.5M | $25.8M | $579.7M | $2.39B | $2.46B | $1.64B | $1.15B | $459.9M |
| Long-term Debt | $316.3M | $317.8M | $319.2M | $320.6M | $322.0M | $323.5M | $166.5M | $168.0M | $169.7M | $244.2M |
| Total Liabilities | $399.8M | $404.2M | $375.9M | $359.0M | $955.3M | $2.93B | $2.89B | $2.51B | $2.18B | $1.30B |
| Retained Earnings | -$930.0M | -$1.11B | -$1.30B | -$1.43B | -$1.87B | -$3.62B | -$4.28B | -$4.82B | -$5.01B | -$4.57B |
| Total Equity | -$5.5M | -$101.7M | -$167.9M | -$186.0M | $627.2M | -$351.7M | -$634.1M | -$716.9M | -$623.8M | -$127.8M |
| Total Debt | $316.3M | $317.8M | $319.2M | $321.9M | $468.0M | $454.0M | $549.8M | $229.1M | $230.4M | $248.8M |
| Net Debt | $172.0M | $211.5M | $249.0M | $243.1M | -$243.1M | -$1.06B | -$787.1M | -$339.4M | -$692.7M | -$486.3M |
| Working Capital | $221.4M | $129.6M | $73.7M | $71.5M | $668.5M | -$235.2M | -$756.6M | -$491.2M | -$25.5M | $518.3M |
Financial Health
| Debt / Equity | -1.55 |
| Current Ratio | 2.33 |
Profitability
| Return on Equity | 159.85% |
| Return on Invested Capital | -36.14% |
| Return on Assets | -25.92% |
| Gross Margin | 77.85% |
| Operating Margin | -54.94% |
| Net Margin | -59.87% |
Related companies: CVAC · NKTR · NTLA · ORIC · PGEN · TERN · TRVI
Explore sector: Healthcare · Biotechnology
More sections of NVAX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks